Inclusion Criteria:

- Histologically or cytologically confirmed diagnosis of advanced and/or metastatic
solid tumor or lymphoma that is refractory to standard therapy

- Measurable or evaluable disease

- Score of 0 to 2 on the ECOG performance scale

Exclusion Criteria:

- Concurrent serious medical illness

- Known, clinically suspected, or history of central nervous system (CNS) tumor
involvement

- Active diarrhea

- Known history of coagulation disorder

- Patients requiring cytochrome P450 3A4 (CYP3A4) enzyme inducing medications

- Requirement for ketoconazole or other strong inhibitor of CYP3A4 enzymes

- Prior chemotherapy, immunotherapy, investigational agent, or other therapy used to
treat the cancer within 4 weeks (6 weeks for prior treatment with mitomycin C or
nitrosoureas) prior to the scheduled administration of EZN-2208